Health disorders in women can be caused by many abnormalities in the body...
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
- Another BACE inhibitor fails in phase III trials
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Customised R&D Services
AntalGenics offers the technology and knowledge required for the management of a wide variety of active ingredient formulation. Its research and development (R&D) capabilities provide high-quality design and development activities to meet the client's requirements.
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
The Optimal Incubation Time for In-Vitro Hemocompatibility Testing
During hemocompatibility testing, activation products may reach plateau values, which can result in less distinction between hemocompatible and hemo-incompatible materials.
B&W Tek’s New Website for Transmission Raman Spectroscopy
B&W Tek is proud to announce the launch of contentuniformity.com, a fully comprehensive website on the QTRam® and the benefits of transmission Raman spectroscopy.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.